Efficacy and Safety of Tavapadon, an Orally Administered, Once-daily, Selective D1/D5 Partial Dopamine Agonist, Adjunctive to Levodopa for Treatment of Parkinson’s Disease with Motor Fluctuations (S37.003)

作者：Hubert H. Fernandez, Stuart Isaacson, Robert A. Hauser, Pinky Agarwal, William G. Ondo, Ariane Park, Lawrence Elmer, Daniel Kremens, Matthew Leoni, Sridhar Duvvuri, Cari Combs, E. Koenig, Ih Chang, Gina Pastino, Stacey Tringali, Nicole Golonski, Raymond Sanchez · 发表于：Neurology · 年份：2025 · DOI：10.1212/wnl.0000000000208468 · 被引用次数：2 · 研究领域：Neurological disorders and treatments、Parkinson's Disease Mechanisms and Treatments、Botulinum Toxin and Related Neurological Disorders

To evaluate the efficacy, safety, and tolerability of tavapadon adjunctive to levodopa in adults with Parkinson’s disease (PD) and motor fluctuations.